# Sanofi Consumer Healthcare India share price today (Sanofi Consumer Healthcare India Ltd, NSE: SANOFICONR)

> Sanofi Consumer Healthcare India share price today: ₹3,495.90 at the NSE close on 3 November 2026, down 27.8% in a year. Sanofi Consumer Healthcare India (NSE: SANOFICONR) is worth ₹8,052 crore, trades at a P/E of 28.7 and has closed between ₹3,207.90 and ₹4,868.40 over the past 52 weeks. > Sanofi Consumer Healthcare India Ltd's earnings have grown faster than its share price. Earnings per share grew +0.0% in a year while the price moved −27.8%. SANOFICONR · Pharma - MNC bulk Drugs · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹3,495.90 (−27.8% in a year)
- P/E: 28.7× (lower than 98% of the last 2.1 years)
- Revenue (Sep 2026): ₹263 Cr (+12.4% on a year ago)
- Profit (Sep 2026): ₹77.0 Cr (+22.2% on a year ago)
- Operating margin: 39.0% (+3.0 points on a year ago)
- ROCE: 90%, FY25
- ROIC: 663.3%, against a 12.0% cost of capital: +651.3 points

The main question: yearly earnings per share moved +0.0% while the share price moved −27.8%. ## What is the Sanofi Consumer Healthcare India share price today? Sanofi Consumer Healthcare India Ltd's share price was ₹3,495.90 at the close on 3 November 2026. It has been falling for 10 weeks. That is 18.6% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 21 weeks running. In the last 52 weeks it traded between ₹3,208 and ₹4,868, and at that close it sat 17% of the way up from that low. Over the last 2.1 years the share price moved −29% while the NIFTY 500 moved −8%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 24 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sanofi Consumer Healthcare India this quarter? 1. Foreign funds (FIIs) cut their stake for 6 quarters in a row From 4.5% to 2.5% of the company by the September 2026 quarter. 2. Indian funds and insurers (DIIs) raised their stake for 5 quarters in a row From 16.9% to 18% of the company by the September 2026 quarter. ## What are Sanofi Consumer Healthcare India's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sanofi Consumer Healthcare India reported revenue of ₹263 crore, up 12.4% from ₹234 crore a year earlier, and a profit of ₹77.0 crore, up 22.2% from ₹63.0 crore. ### Sanofi Consumer Healthcare India results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹263 crore | ₹234 crore | +12.4% |
| Profit | ₹77.0 crore | ₹63.0 crore | +22.2% |
| Earnings per share | ₹33.26 | ₹27.31 | +21.8% |
| Operating margin | 39.0% | 36.0% | +3.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Sanofi Consumer Healthcare India share price history? Sanofi Consumer Healthcare India closed at ₹3,495.90 on 3 November 2026, down 27.8% from ₹4,842.60 a year earlier (31 October 2025). Its highest weekly close since September 2024 was ₹5,371.50 on 4 July 2025. ### Sanofi Consumer Healthcare India share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹3,207.90 | +9.0% |
| 1 month ago · 1 Oct 2026 | ₹3,787.20 | −7.7% |
| 6 months ago · 30 Apr 2026 | ₹4,763.90 | −26.6% |
| 1 year ago · 31 Oct 2025 | ₹4,842.60 | −27.8% |
| Earliest weekly close in our records · 13 Sep 2024 | ₹4,903.50 | −28.7% |
| Highest weekly close since September 2024 · 4 Jul 2025 | ₹5,371.50 | −34.9% |
| Lowest weekly close since September 2024, also the 52-week low · 23 Oct 2026 | ₹3,207.90 | +9.0% |
| 52-week high (weekly close) · 15 May 2026 | ₹4,868.40 | −28.2% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (119 weekly closes from 13 September 2024 to 3 November 2026.)

## What is the latest news on Sanofi Consumer Healthcare India? 3 Nov 2026: Sanofi Consumer Healthcare India closed at ₹3,495.90, up 9.0% on the week and down 7.7% on the month. Results for July to September 2026: Revenue up 12.4% and profit up 22.2% on a year earlier. ### Earlier

- 19 Jun 2026: ex-date for a dividend of ₹75 a share. ## What dividend does Sanofi Consumer Healthcare India pay? Sanofi Consumer Healthcare India paid ₹75 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 2.15% at the ₹3,495.90 close on 3 November 2026. The last was a dividend of ₹75 a share, ex-date 19 June 2026. ### Sanofi Consumer Healthcare India dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 19 Jun 2026 | ₹75 | Dividend |
| 17 Apr 2025 | ₹55 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Sanofi Consumer Healthcare India Ltd paid out 72% of its profit as dividends in FY25, and it paid a dividend in 3 of its last 4 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Sanofi Consumer Healthcare India on? Sanofi Consumer Healthcare India is on 2 of our India lists: Dividend stocks and Pharma stocks. - [Dividend stocks Regular dividend yield (%): 2.13](https://www.sectoralpha.in/dividend-stocks-india)
- [Pharma stocks Market value (₹ crore): 8107.412369636579](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Sanofi Consumer Healthcare India profitable? Sanofi Consumer Healthcare India Ltd earned ₹77.0 Cr of net profit in the Sep 2026 quarter, +22.2% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY25 profit was ₹240 Cr. Over 2 years profit has grown 20.6% a year on average. That is 29.3% of the quarter's revenue. The same quarter a year earlier earned ₹63.0 Cr. For the full year, FY25 profit was ₹240 Cr (+0.0% on the year before). Why profit moved: revenue changed +12.4% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +30.3% and revenue +24.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sanofi Consumer Healthcare India make, and is it growing? Sanofi Consumer Healthcare India Ltd reported ₹263 Cr of revenue in the Sep 2026 quarter, +12.4% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 2 years it has grown 25.8% a year on average. The last full year, FY25, came in at ₹878 Cr. The last four reported quarters add to ₹979 Cr. FY25 revenue was ₹878 Cr, +0.0% on the year before. Recent pace: the last four quarters grew +24.6% on average, against 25.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +22.5%, against +12.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +28.4%, against +16.9% a year (accelerating). ## How much of every ₹100 of sales does Sanofi Consumer Healthcare India keep? Sanofi Consumer Healthcare India Ltd's operating margin was 39.0% in the Sep 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 4 years it has been between 35.0% and 39.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.3 percentage points on the year while gross margin changed +1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Sanofi Consumer Healthcare India's profit turning into cash? Over the last 3 years, 105% of Sanofi Consumer Healthcare India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in ₹175 Cr of operating cash against ₹240 Cr of profit. After ₹18.0 Cr of spending on assets, ₹157 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 105% of profit came in as cash: the cash cycle got 125 days shorter between FY23 and FY25, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 2.8× depreciation over three years. The next section checks what that spending is building. ## Where does Sanofi Consumer Healthcare India's cash go? Sanofi Consumer Healthcare India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −16 days in FY25, down from 109 days in FY23. It spent ₹44.0 Cr on assets over the last 2 years. Customers take 12 days to pay, and stock sits for 98 days on average. At FY25 sales of ₹878 Cr, each day of that cycle ties up about ₹2.4 Cr, so roughly −₹38.0 Cr is tied up in the business at any time. FY25: customers took 12 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of −16 days, shorter than FY23's 109. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 12 days after that. Suppliers are paid at 126 days. Together that makes the −16-day cycle. Spending on assets: ₹44.0 Cr over the last 2 years, against ₹16.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY25): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Sanofi Consumer Healthcare India's P/E ratio, and how does it compare with its own history? Sanofi Consumer Healthcare India Ltd's P/E is 28.7×, about the lowest it has ever been. Its usual P/E (the middle reading) is 48.6×, over 2.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +0.0% while the price moved −27.8%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sanofi Consumer Healthcare India business getting better or worse? Sanofi Consumer Healthcare India Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: revenue growth has eased from +46.8% at its peak to +12.4% (from single-quarter figures), but the business is still expanding, with ROCE rising at 112.6%. This is based on 11 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Sanofi Consumer Healthcare India earn on its capital? Sanofi Consumer Healthcare India Ltd earned a ROCE of 90% in FY25. Its return on capital used (ROIC) is 651.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 27.3% net margin and 1.61× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 27.3% net margin × 1.61× asset turnover × 1.42× leverage (assets divided by equity) ≈ 62.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 663.3% − 12.0% = +651.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. ## Does Sanofi Consumer Healthcare India have too much debt? Sanofi Consumer Healthcare India Ltd has total debt of ₹21.0 Cr against shareholder equity of ₹348 Cr as of Sep 2026, so its debt is 0.06× its equity, which is very little. Year by year, that ratio went from 0.07 in FY25 to 0.07 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sanofi Consumer Healthcare India shareholding pattern? Promoters raised their stake in Sanofi Consumer Healthcare India Ltd by 10.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 71.3% of the company. Domestic institutions moved −5.8 points over the same period, to 18.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +10.9 points over 8 quarters, to 71.3%; Domestic institutions: −5.8 points over 8 quarters, to 18.0%; Foreign institutions: −2.7 points over 8 quarters, to 2.5%. Why the owners changed: promoters drove it (+10.9 points), with the other side taken by domestic institutions (−5.8 points). They raised their stake step by step. ## How far is Sanofi Consumer Healthcare India from balance-sheet trouble? For Sanofi Consumer Healthcare India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sanofi Consumer Healthcare India rank in its industry? 58.7 out of 100, rank 3 of 8 in Pharma - MNC bulk Drugs, with 93% of the evidence available. Sanofi Consumer Healthcare India Ltd scores 58.7 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 3. Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. The four parts add up to the total exactly: 23.7 + 21.5 + 13.5 + 0 = 58.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sanofi Consumer Healthcare India compared with? Sanofi Consumer Healthcare India ranks 3 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 58.7 out of 100. 1. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) PGHL · quiet · Most evidence points up · 81% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 12.6% · Profit 19.3% · Operating margin change 0 points · 88% evidence Capital efficiency 16.6/25 · ROCE 83.9% · Operating margin 27% · 100% evidence Valuation 13.1/20 · P/E 28.2× · PEG 1.23 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.5% · 1 year -8% · 25% evidence · 1 of 12 weeks ahead Exact sum: 24.1 + 16.6 + 13.1 + 12 = 65.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) GLAXO · losing its lead · Evidence leans up · 96% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 5.8% · Profit 12.4% · Operating margin change 0 points · 88% evidence Capital efficiency 19.1/25 · ROCE 61.4% · Operating margin 31% · 100% evidence Valuation 6.4/20 · P/E 40.1× · PEG 4.12 · 100% evidence Relative strength 15.2/20 · Lead over its industry 2% · Lead over NIFTY 500 4.3% · 1 year -4.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.1 + 19.1 + 6.4 + 15.2 = 58.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. Sanofi Consumer Healthcare India Ltd this page SANOFICONR · quiet · Evidence leans up · 93% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 22.5% · Profit 28.4% · Operating margin change 3 points · 100% evidence Capital efficiency 21.5/25 · ROCE 89.9% · Operating margin 39% · 100% evidence Valuation 13.5/20 · P/E 28.3× · PEG 1.07 · 65% evidence Relative strength 0.0/20 · Lead over its industry -19.5% · Lead over NIFTY 500 -17.6% · 1 year -28.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.7 + 21.5 + 13.5 + 0 = 58.7 · What this means: Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. 4. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) PFIZER · quiet · Evidence leans up · 96% evidence 52.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.8/35 · Revenue 10.6% · Profit -9.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.7/25 · ROCE 24.1% · Operating margin 38% · 100% evidence Valuation 19.6/20 · P/E 21.9× · PEG 0.73 · 100% evidence Relative strength 3.4/20 · Lead over its industry -18.8% · Lead over NIFTY 500 -16.8% · 1 year -29.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.8 + 15.7 + 19.6 + 3.4 = 52.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ABBOTINDIA · quiet · Evidence leans up · 81% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 6.3% · Profit 11.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.2/25 · ROCE 44.8% · Operating margin 29% · 100% evidence Valuation 7.9/20 · P/E 33.7× · PEG 3.6 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.6% · 1 year -11.6% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.9 + 15.2 + 7.9 + 10.1 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) SANOFI · turning · Evidence leans down · 100% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue -5.7% · Profit 2.5% · Operating margin change 5 points · 100% evidence Capital efficiency 15.6/25 · ROCE 57.5% · Operating margin 33% · 100% evidence Valuation 7.4/20 · P/E 20.2× · PEG 3.22 · 100% evidence Relative strength 10.3/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -5.7% · 1 year -33% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 15.6 + 7.4 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) NOVARTIND · breaking out · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 5.4% · Profit -4.9% · Operating margin change 3 points · 88% evidence Capital efficiency 8.1/25 · ROCE 16.3% · Operating margin 34% · 100% evidence Valuation 5.6/20 · P/E 42.7× · PEG 1.96 · 100% evidence Relative strength 16.7/20 · Lead over its industry 40.3% · Lead over NIFTY 500 41.9% · 1 year 95.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.2 + 8.1 + 5.6 + 16.7 = 45.6 · What this means: Relative strength against the index is 41.9%, and revenue and profit growth are weak. 8. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ASTRAZEN · basing · Most evidence points down · 74% evidence 30.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 31.2% · Profit -7.1% · Operating margin change -8 points · 88% evidence Capital efficiency 8.1/25 · ROCE 29.3% · Operating margin 7% · 100% evidence Valuation 4.1/20 · P/E 91.7× · PEG 3.95 · 65% evidence Relative strength 8.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.4% · 1 year -33.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 10 + 8.1 + 4.1 + 8 = 30.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - MNC bulk Drugs](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs), all 8 compared on one page. ## Which companies are close to Sanofi Consumer Healthcare India in size? Sanofi Consumer Healthcare India is the 6th largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Glaxosmithkline Pharmaceuticals, Pfizer, Astrazeneca Pharma India and Procter & Gamble Health. Just below it: Sanofi India and Novartis India. ### Pharma - MNC bulk Drugs companies close in size

1. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) ₹42,255 crore
2. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) ₹16,871 crore
3. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore
4. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) ₹9,413 crore
5. Sanofi Consumer Healthcare India Ltd ₹7,928 crore
6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) ₹7,379 crore
7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) ₹4,179 crore

[All 8 Pharma - MNC bulk Drugs companies, largest first](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs#all-companies)

### Companies close in size in other industries

1. [AXISCADES Technologies Ltd](https://www.sectoralpha.in/stocks/axiscades-technologies-ltd) ₹7,979 crore · Aerospace & Defence - Equipments
2. [Sudarshan Chemical Industries Ltd](https://www.sectoralpha.in/stocks/sudarshan-chemical-industries-ltd) ₹7,930 crore · Dyes & Pigments
3. Sanofi Consumer Healthcare India Ltd ₹7,928 crore
4. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) ₹7,914 crore · Pharma - API
5. [Indus Infra Trust](https://www.sectoralpha.in/stocks/indus-infra-trust) ₹7,902 crore · Infra/Real Estate Investment Trust

## What else do people ask about Sanofi Consumer Healthcare India? ### What is Sanofi Consumer Healthcare India's share price today? Sanofi Consumer Healthcare India Ltd's share price is ₹3,495.90, −27.8% over the past year. The whole company is worth ₹8,052 Cr on the market. In the last 52 weeks it traded between ₹3,208 to ₹4,868; today it is 17% of the way up from the low, 18.6% below its 200-day average (as of 3 November 2026). ### What were Sanofi Consumer Healthcare India's latest quarterly results? Sanofi Consumer Healthcare India Ltd reported revenue of ₹263 Cr and net profit of ₹77.0 Cr for the Sep 2026 quarter. Revenue rose 12.4% and profit rose 22.2% compared with a year earlier. Earnings per share were ₹33.26 (as of 3 November 2026). ### What is Sanofi Consumer Healthcare India's market cap? Sanofi Consumer Healthcare India Ltd's market capitalisation is ₹8,052 Cr at a share price of ₹3,495.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sanofi Consumer Healthcare India performing? Sanofi Consumer Healthcare India Ltd's share price has been falling for 10 weeks. In its latest quarter, revenue rose 12.4% and profit rose 22.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 21 weeks running (as of 3 November 2026). ### Will Sanofi Consumer Healthcare India's share price go up? This page does not forecast Sanofi Consumer Healthcare India Ltd's share price. What it shows instead: the share price is ₹3,495.90, and it has been falling for 10 weeks. Its P/E of 28.7× is higher than 2% of its own last 2 years (as of 3 November 2026). ### Who owns Sanofi Consumer Healthcare India? Promoters own 71.3% of Sanofi Consumer Healthcare India Ltd, foreign institutions 2.5%, domestic institutions 18.0% and the public 8.2% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 10.9 percentage points over 8 quarters (as of 3 November 2026). ### Does Sanofi Consumer Healthcare India have too much debt? No, Sanofi Consumer Healthcare India Ltd has little debt: its debt is 0.07× its equity, and its operating profit is more than 100 times its interest bill. FY25 borrowings were ₹25.0 Cr against equity of ₹384 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Sanofi Consumer Healthcare India in its business cycle? Sanofi Consumer Healthcare India Ltd's FY25 operating margin was 35.0%, against a 4-year range of 35.0% to 39.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 39.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sanofi Consumer Healthcare India story? The main question: yearly earnings per share moved +0.0% while the share price moved −27.8%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sanofi Consumer Healthcare India a stock worth studying right now? What the numbers show: Sanofi Consumer Healthcare India Ltd's earnings have grown faster than its share price. Earnings per share grew +0.0% in a year while the price moved −27.8%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.